Informations sur le produit
Ranolazine is an anti-anginal drug that belongs to the class of nitrates and calcium channel blockers. It is a prodrug that undergoes first-pass metabolism in the liver to form its active metabolite, ranolazine-d3. Ranolazine-d3 has been shown to be more potent than ranolazine with a lower dose requirement, and it may also have fewer side effects such as dizziness and lightheadedness. In this study, ranolazine was given orally at doses of 50mg, 100mg, 200mg, or 400mg per day for 28 days. The pharmacokinetic parameters were determined by high performance liquid chromatography (HPLC). The population consisted of healthy volunteers (n=30) who were matched for age and gender. Subjects received a single dose of either placebo or ranolazine at one of the four doses listed above. Blood samples were taken at baseline and after 14 hours post-dose on day 1, 8, 15
